Module 3  Specific Interventions to Prevent MTCT

SESSION 1  Antiretroviral Treatment and Prophylaxis for the Prevention of MTCT
SESSION 2  Antenatal Management of Women who are Infected with HIV and Women with Unknown HIV Status
SESSION 3  Management of Labour and Delivery of Women who are HIV-Infected and Women with Unknown HIV Status
SESSION 4  Immediate Postpartum Care of Women who are HIV-Infected and Women with Unknown HIV Status
SESSION 5  Immediate Newborn Care of Infants who are HIV-Exposed and Infants with Unknown HIV Status

After completing the module, the participant will be able to:

- Name specific interventions for preventing mother-to-child transmission (PMTCT).
- List locally available and recommended antiretroviral (ARV) regimens.
- Discuss the antenatal management of women infected with HIV and women whose HIV status is unknown.
- Explain the management of labour and delivery in women infected with HIV and women whose HIV status is unknown.
- Explain postpartum care of women infected with HIV and women whose HIV status is unknown.
- Explain immediate newborn care of infants born to mothers who are HIV-infected and mothers whose HIV status is unknown.
<table>
<thead>
<tr>
<th>Session 1</th>
<th>National policy/guidelines on antiretroviral treatment and prophylaxis for the prevention of MTCT (PMTCT)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Session 2</td>
<td>National guidelines on antenatal care (ANC) for women infected with HIV</td>
</tr>
<tr>
<td></td>
<td>ANC/PMTCT confidentiality policy, policy on recording HIV status in patient's medical record (if not included in national guidelines)</td>
</tr>
<tr>
<td>Session 3</td>
<td>National policy on management of labour and delivery for women infected with HIV and women with unknown HIV status</td>
</tr>
<tr>
<td></td>
<td>National policy on testing and counselling during labour</td>
</tr>
<tr>
<td>Session 4</td>
<td>National guidelines on immediate postpartum care of women infected with HIV and women with unknown HIV status</td>
</tr>
<tr>
<td>Session 5</td>
<td>National guidelines on immediate newborn care of infants who are HIV-exposed and infants with unknown HIV status</td>
</tr>
</tbody>
</table>

The Pocket Guide contains a summary of each session in this module.
ARV treatment
ARV drugs are effective for both treating maternal HIV infection and preventing MTCT. Several antiretroviral regimens reduce the risk of MTCT in both breastfeeding and non-breastfeeding women. The mechanisms by which these regimens prevent or reduce mother-to-child HIV transmission include decreasing viral replication in the mother, leading to a decrease in viral load in the infant and/or prophylaxis during and after exposure to the virus.

Pregnant women who are HIV-infected need ARV treatment for their own health should receive it, according to the treatment guidelines recommended by WHO. ARV treatment during pregnancy, when indicated, will improve the health of the woman and decrease the risk of transmission of HIV to the infant.

ARV treatment is recommended in the following situations: For detailed information, please refer to Appendix 1-A.

If CD4 testing is available, it is recommended that baseline CD4 counts be documented and ARV treatment offered to patients with:

- WHO Stage IV disease, irrespective of CD4 cell count
- WHO Stage III disease (including but not restricted to HIV wasting, chronic diarrhoea of unknown aetiology, prolonged fever of unknown aetiology, pulmonary TB, recurrent invasive bacterial infections, or recurrent or persistent mucosal candidiasis); with consideration of using CD4 cell counts of less than 350/mm$^3$ to assist with decision-making$^a$
- WHO Stage I or II disease with CD4 cell counts of 200/mm$^3$ or lower$^b$

$^a$ CD4 count advisable to assist with determining need for immediate therapy. For example, pulmonary TB can occur at any CD4 level, and other conditions can be mimicked by non-HIV aetiologies (eg, chronic diarrhoea, prolonged fever).

$^b$ The precise CD4 count above 200/mm$^3$ at which ARV treatment should be initiated has not been established.
If CD4 testing is unavailable, it is recommended that ARV treatment be offered to patients with:

- **WHO Stage IV disease**, irrespective of total lymphocyte count
- **WHO Stage III disease** (including but not restricted to wasting, chronic diarrhoea of unknown aetiology, prolonged fever of unknown aetiology, pulmonary TB, recurrent invasive bacterial infections, or recurrent/ persistent mucosal candidiasis), irrespective of total lymphocyte count
- **WHO Stage II disease**, with a total lymphocyte count of less than or equal to 1,200/mm$^3$

The recommendation to start ARV treatment in all patients with stage III disease, without reference to total lymphocyte counts reflects a consensus of experts. The discussion took into account the need for a practical recommendation that allows clinical services and TB programmes in severely constrained settings to offer access to ARVs to their patients. As some adults and adolescents with stage III disease will be presenting with CD4 counts above 200/mm$^3$, some of them will receive antiretroviral treatment before the CD4 less than 200/mm$^3$ threshold is reached. However, if CD4 counts cannot be determined, the experts did not consider starting ARVs earlier in these patients to be problematic.

A total lymphocyte count of less than or equal to 1,200/mm$^3$ can be substituted for the CD4 count when the latter is unavailable and HIV-related symptoms exist. It is not useful in the asymptomatic patient. Thus, in the absence of CD4 cell testing, asymptomatic HIV-infected patients (WHO Stage I) should not be treated because there is currently no other reliable marker in severely resource-constrained settings.

**ARV treatment during pregnancy**

For women diagnosed with HIV during pregnancy and eligible for treatment with ARVs, treatment should be initiated as soon as possible. The start of treatment may be delayed until after the first trimester. However, when the woman is severely ill, the benefits of treatment outweigh any potential risk to the foetus. Efavirenz (EFV), an antiretroviral drug that is considered potentially teratogenic is not recommended until after the first trimester of pregnancy and should be avoided in women of childbearing age unless effective contraception can be ensured. Module 3 Appendix 3-B provides guidance for the use of antiretroviral drugs in pregnant women and women of childbearing age.

**Pregnant women receiving ARV therapy**

Pregnant women receiving ARV therapy require ongoing care and monitoring within the local HIV/AIDS programme. When co-infection with TB exists, additional drug therapy and clinical management are required to minimise side effects that may occur when ARV drugs are coadministered with TB therapy.

**ARV prophylaxis**

Women who do not need treatment (ie, women who are not “eligible” for treatment based on the criteria above), or do not have access to treatment, should be offered prophylaxis to prevent MTCT using one of a number of ARV regimens known to be effective. ARV prophylaxis regimens vary and are selected based on efficacy, safety, drug resistance, feasibility, and acceptability. Please refer to Appendix 3-A for a complete listing of ARV prophylaxis regimens.

**The first choice prophylaxis regimen for PMTCT**

Zidovudine (ZDV) starting at 28 weeks of gestation, or as soon as possible thereafter and intrapartum every 3 hours until delivery plus single-dose nevirapine (NVP) at the onset of labour for the mother, and single-dose NVP plus one week of ZDV for the infant.
Drug information

Zidovudine (ZDV, AZT)
- Absorbed rapidly and completely after oral administration
- Prenatal and neonatal exposure to ZDV is generally well tolerated
- Mild anaemia may occur but usually resolves when treatment ends
- May be taken with or without food

Nevirapine (NVP)
- Absorbed rapidly and completely after oral administration and crosses the placenta quickly
- Long half-life that benefits the infant
- May be taken with or without food

Lamivudine (3TC)
- Absorbed rapidly and completely after oral administration
- May safely be taken with other medications that treat HIV-related symptoms
- May be taken with or without food

WHO recommendations on longer prophylaxis regimens
Until recently, the emphasis of PMTCT guidelines has been on short-course prophylaxis (eg short-course zidovudine or short-course nevirapine in resource-constrained settings). New recommendations from WHO (2004) emphasise longer, combination prophylaxis regimens, where feasible, while recognising the need for short-course prophylaxis where longer regimens have not been provided or are not feasible.
Antenatal care

Antenatal care improves the general health and well being of mothers and their families. Given the rapid spread of HIV infection worldwide, all pregnant women may be considered at risk for acquiring HIV infection.

The ANC setting is a main source of health care for women of childbearing age. By integrating PMTCT services into essential ANC services, healthcare programmes can improve care—and pregnancy outcomes—for all their clients.

This session addresses integrating PMTCT services for and antenatal management of women infected with HIV and women of unknown HIV status within the context of ANC programmes.

Antenatal interventions can reduce the risk of MTCT. Good maternal health care helps women with HIV infection stay healthy longer and care for their children better. When mothers die prematurely, their children face higher rates of illness and death.

For the successful implementation of PMTCT programmes, the following elements need to be included as part of ANC:

- Health information and education
- Education about safer sex practices and HIV
- HIV testing and counselling
- Partner HIV testing and counselling
- Interventions to reduce the risk of MTCT
- Infant-feeding counselling and support for Safe Motherhood including malaria and TB treatment
- Diagnosis and treatment of sexually transmitted infections (STIs)

Antenatal care of women infected with HIV

ANC for women infected with HIV includes the basic services recommended for all pregnant women. However, obstetric and medical care should be expanded to address the specific needs of women infected with HIV. (See Table 3.1.)

HIV infection in women of childbearing age presents a great challenge in resource-limited settings. Determining a woman’s HIV status is the first step in providing appropriate treatment, care and support services, including access to antiretroviral prophylaxis when indicated. Availability of rapid testing allows women to be tested and receive their HIV test results at the first prenatal visit. When HIV status is known, mothers can be evaluated for ARV eligibility and offered the ARV treatment and prophylaxis indicated, if available.

In some situations, because of the lack of accessible testing services or because a woman refuses to be tested, her HIV status may remain unknown. In such circumstances, the woman should be considered at risk for MTCT, and she should be counselled accordingly during ANC. Women of unknown HIV status should be made aware that testing is available at later ANC visits and be reminded of the benefits of knowing their HIV status.
**Preventing opportunistic infections**

Preventing opportunistic infections (OIs) can reduce rates of illness and death among pregnant women who are HIV-infected. It also can reduce the risk of adverse pregnancy outcomes, such as preterm labour and delivery, which can increase the risk of MTCT.

---

**Prevention, screening, and treatment for TB, a leading cause of mortality among persons who are HIV-infected, is particularly important. Module 7, Appendix 7-A contains information on tuberculosis.**

---

Healthcare workers should pay special attention to signs and symptoms of possible opportunistic infections and follow protocols for prophylaxis of common problems. In Module 7, Appendix 7-C provides information about *pneumocystis carinii* pneumonia (PCP) prophylaxis.

**Assessment and management of HIV-related illnesses**

HIV-related illnesses can increase the risk of MTCT. Women should be monitored for signs or symptoms of progressive HIV/AIDS.

**Recurrent or chronic infection**

Women infected with HIV are susceptible to other infections that can be treated in keeping with local protocols. Examples include the following:

- TB
- Urinary tract infections
- Respiratory infections
- Recurrent vaginal candidiasis
- Malaria

**Psychosocial and community support**

Pregnancy is a time of unique stress, and healthcare workers may consider assessing the amount of support a woman is receiving from family and friends. Women with HIV usually have additional concerns related to their own health, their child's health, confidentiality, and the possibility that their HIV status might be disclosed to other people. Referrals to AIDS support organisations and clubs should be made.
Table 3.1 Essential Package of Integrated Antenatal Care Services

<table>
<thead>
<tr>
<th>Client history:</th>
<th>Obtain routine data including medical, obstetric, and psychosocial history. Determine drug history, known allergies, and use of alternative medicines such as herbal products.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical exam and vital signs:</td>
<td>Include visual and hands-on exam and assess for current signs or symptoms of illness including AIDS, tuberculosis (TB), malaria and sexually transmitted infections (STIs).</td>
</tr>
<tr>
<td>Abdominal exam:</td>
<td>Include speculum and bimanual exams, where acceptable and feasible.</td>
</tr>
<tr>
<td>Lab diagnostics:</td>
<td>Perform routine serology for syphilis including testing for anaemia. Perform HIV testing as per country protocol based on availability and informed consent. When woman is HIV-positive, obtain CD4 count and RNA polymerase chain reaction (PCR) (measures viral load, response to ARV treatment), when available.</td>
</tr>
<tr>
<td>Nutritional assessment and counselling:</td>
<td>Include iron and folate supplementation, monitor for anaemia, adequate caloric and nutrient intake, and recommend realistic diet adjustments based on local resources.</td>
</tr>
<tr>
<td>STI screening:</td>
<td>Include risk assessment for STIs. Diagnose and treat early according to protocols. Counsel about STIs, signs and symptoms and increased risk of HIV transmission. Educate to avoid transmission or re-infection.</td>
</tr>
<tr>
<td>Opportunistic Infection (OI) Prophylaxis:</td>
<td>Provide prophylaxis based on country protocols.</td>
</tr>
<tr>
<td>Screening and care for other infections:</td>
<td>Screen and treat any locally prevalent parasitic, bacterial, or fungal infections, including helminth infections. Treat herpes, candidiasis, PCP, and any other AIDS-related OIs.</td>
</tr>
<tr>
<td>Tuberculosis (TB):</td>
<td>Co-infection with tuberculosis is the leading cause of HIV mortality. All women presenting for ANC services with a cough of more than 2 weeks' duration should be screened for TB, regardless of HIV status. Specific treatment protocols are recommended for women infected with HIV, pregnant women, and women already receiving antiretroviral therapy.</td>
</tr>
<tr>
<td>Antimalarials:</td>
<td>Malaria is a major cause of high maternal and infant morbidity and mortality and is linked to increased MTCT (via placental infection). Malaria prophylaxis is needed in endemic areas; identify acute cases and treat aggressively and promptly. Use insecticide on bed nets where possible.</td>
</tr>
<tr>
<td>ARV prophylaxis during pregnancy:</td>
<td>Provide in accordance with country PMTCT protocol.</td>
</tr>
<tr>
<td>ARV treatment during pregnancy:</td>
<td>Refer for treatment when indicated according to country protocols.</td>
</tr>
<tr>
<td>Counselling on infant feeding:</td>
<td>All women require infant-feeding counselling and support. When women do not know their HIV status, exclusive breastfeeding should be promoted and supported. Women infected with HIV should consider replacement feeding when it is feasible, acceptable, affordable, accessible, and safe; otherwise, exclusive breastfeeding with early cessation is recommended.</td>
</tr>
<tr>
<td>Counselling on pregnancy danger signs:</td>
<td>Provide women with information and instructions on seeking early care for pregnancy complications such as bleeding, fever and pre-eclampsia.</td>
</tr>
<tr>
<td>Counselling on HIV/AIDS danger signs:</td>
<td>Provide women with information and instructions on seeking health care for symptoms of HIV disease progression, such as opportunistic infections, chronic persistent diarrhoea, candidiasis, fever or wasting. Refer women to AIDS treatment programmes when indicated and available.</td>
</tr>
<tr>
<td>Partners and family:</td>
<td>HIV-related stress and lack of support have been linked to progression of HIV infection. Refer women, partners, and families to community-based support clubs or organisations when possible.</td>
</tr>
<tr>
<td>Effective contraception plan:</td>
<td>Counsel about consistent use of condoms during pregnancy, as well as throughout postpartum and breastfeeding periods to avoid new infection, re-infection and further transmission. Include long-term family planning with partner involvement when possible.</td>
</tr>
</tbody>
</table>
**Exercise 3.1 Antenatal care: case studies**

| **Purpose** | To review national or local policies on ANC and PMTCT.  
|            | To review antenatal management practices for women infected with HIV. |
| **Duration** | 25 minutes |
| **Instructions** | **Part 1**  
|                  | - Take a few minutes to become familiar with the national or local policies on ANC and PMTCT.  
|                  | - Review the key points of the policies that the facilitator has written on the flipchart.  
|                  | - Share your perceptions of how these policies are/are not applied in your clinical setting.  
| **Part 2** | - Review copies of the two antenatal case studies, Exercise 3.1, and think about your responses to the questions posed.  
|                  | - Share your perceptions on the similarities and differences in these case studies and the situations you encounter in your work setting.  
|                  | - Describe HIV/PMTCT-related experiences that you have found challenging in the ANC setting. |

**Case study 1**
Selma, a 22-year-old single woman, tested HIV-positive at her first antenatal visit at 24 weeks gestation. At that time, she received post-test counselling and was encouraged to bring her partner in for testing. She is now 28 weeks pregnant with her first child.

*What are the ANC management steps that should be taken?*

**Case study 2**
You are an antenatal clinic midwife. Louisa, your patient, is 30 weeks pregnant. When you ask her about her delivery plans, she says that she wants to have the baby at home. She informs you that this is her third child and even though she is HIV-infected, this pregnancy (like her previous two) has been a healthy pregnancy. You can see that she is determined to have a home delivery.

*What do you tell Louisa?*

Consider how you would approach meeting ANC and PMTCT care needs in the context of home delivery. *What would your next steps be?*
Interventions that can reduce MTCT include the following:

Administer ARV treatment and prophylaxis during labour in accordance with national protocols.
- Continue ARV treatment/prophylaxis or implement ARV prophylaxis at labour to reduce maternal viral load and provide protection to the infant.

Use good infection prevention practices for all patient care.
- Use universal precautions, which include use of protective gear, safe use and disposal of sharps, sterilisation of equipment, and safe disposal of contaminated materials.
  (For additional information, see Module 8: Safety and Supportive Care in the Work Environment.)

Minimise cervical examinations.
- Perform cervical examination only when absolutely necessary and with appropriate clean technique.

Avoid prolonged labour.
- Consider using oxytocin to shorten labour when appropriate.
- Use noninvasive foetal monitoring to assess need for early intervention.

Avoid routine rupture of membranes.
- Use a partogram to measure the progress of labour.
- Avoid artificial rupture of membranes, unless necessary.

Avoid unnecessary trauma during delivery.
- Avoid invasive procedures, including scalp electrodes or scalp sampling.
- Avoid routine episiotomy.
- Minimise the use of forceps or vacuum extractors.
Minimise the risk of postpartum haemorrhage.
- Actively manage the third stage of labour.
- Give oxytocin immediately after delivery.
- Use controlled cord traction.
- Perform uterine massage.
- Repair genital tract lacerations.
- Carefully remove all products of conception.

Use safe transfusion practices.
- Minimise the use of blood transfusions.
- Use only blood screened for HIV and when available syphilis, malaria, and hepatitis B and C.

Considerations regarding mode of delivery
Cesarean section, when performed before the onset of labour or membrane rupture, has been associated with reduced MTCT.

Consider the benefits and risks of vaginal delivery versus elective caesarean section, including the safety of the blood supply and the risk of complications.

Strategies to reduce MTCT risk in women with unknown HIV status
In some cases, a woman presents to the health service at the time of labour without knowing her HIV status. She may not have received ANC or been offered HIV testing and counselling, she may have refused HIV testing, or may not have received her test result. In order to prevent MTCT in women with unknown HIV status the following steps may be taken:

Testing and counselling during labour
If rapid testing is available (See Module 6: HIV Testing and Counselling for PMTCT):
- Offer rapid HIV testing with right to refuse.
- Mention benefits of the HIV test:
  - If positive, ARVs can be administered for PMTCT and referral for treatment and care can be made.
- Describe the testing process.
- Provide post-test counselling.

It may be difficult to offer counselling or obtain informed consent during labour. The healthcare worker should remain sensitive and supportive to the woman. Rapid testing can be done in labour with post-test counselling provided after delivery.

Providing ARVs at labour and delivery
ARV prophylaxis can be provided to the mother who is HIV-infected and the infant to prevent MTCT. (See Appendix 3-A for the complete listing of recommended regimens.)
Providing ARV prophylaxis without testing
- Consider only as a last resort in high prevalence areas when no rapid testing is available.
- Use single dose nevirapine as the prophylactic regimen.
- Provide testing, counselling, and related PMTCT services postpartum.

<table>
<thead>
<tr>
<th>Exercise 3.2 Labour and delivery ARV prophylaxis: case studies</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Purpose</strong></td>
</tr>
<tr>
<td>To review national policies on testing and counselling during labour and on ARV prophylaxis</td>
</tr>
<tr>
<td>To discuss administering ARV prophylaxis during labour and delivery</td>
</tr>
<tr>
<td><strong>Duration</strong></td>
</tr>
<tr>
<td>25 minutes</td>
</tr>
<tr>
<td><strong>Instructions</strong></td>
</tr>
<tr>
<td><strong>Part 1</strong></td>
</tr>
<tr>
<td>- Take a few minutes to become familiar with the national policies on testing and counselling in labour and on ARV prophylaxis.</td>
</tr>
<tr>
<td>- Review the key points written on the flipchart.</td>
</tr>
<tr>
<td>- Comment on how these policies are applied in your clinical setting and share the challenges and obstacles you face when applying these policies in your practice.</td>
</tr>
<tr>
<td><strong>Part 2</strong></td>
</tr>
<tr>
<td>- Review the 2 case studies below.</td>
</tr>
<tr>
<td>- Think about the questions posed in the case studies and participate in the group discussion to answer the questions.</td>
</tr>
<tr>
<td>- Review the key points written on the flipchart.</td>
</tr>
<tr>
<td>- Share your perspective on the similarities and differences in these case studies and the situations you encounter in your clinical setting.</td>
</tr>
<tr>
<td>- Describe challenging HIV/PMTCT experiences in the labour and delivery care setting.</td>
</tr>
</tbody>
</table>

**Case study 1**
Consuelo arrives at the labour and delivery unit. This is her first baby. She hands you her ANC card, which indicates that she was tested during pregnancy and is infected with HIV. Her water broke 4 hours ago and her contractions are now less than 3 minutes apart. Consuelo earlier received a NVP tablet to take at home. When you examine her, you find that she is 5 centimetres dilated.

**After providing general support during labour, what is your first priority?**

**If you discover that she has not taken her NVP tablet, what do you do?**

**Case study 2**
Deborah arrives to deliver. This is her fourth child and she tells you that she has had a good pregnancy. Deborah has received no antenatal care and was never tested for HIV. At this time, her contractions are regular and about 2 minutes apart. During your examination, you find that she is 7 centimetres dilated.

**Considering your national policy on testing and counselling during labour and delivery, what are your next steps?**
SESSION 4 Immediate Postpartum Care of Women who are HIV-Infected and Women with Unknown HIV Status

Postpartum care of women infected with HIV
When providing postpartum care to women infected with HIV, healthcare workers may follow routine protocols, but several areas require additional attention:

Continuing care
Encourage and make plans for continued health care in the following areas:
- Routine gynaecologic care, including pap smears, if available.
- Ongoing treatment, care and support for HIV/AIDS and opportunistic infections along with nutritional support.
- Treatment and monitoring of TB and malaria.
- Referral for antiretroviral treatment (or treatment eligibility)
- Referral for prophylaxis and treatment of OIs.
(For additional information, see Module 7, Linkages to Treatment, Care and Support for Mothers and Families with HIV Infection.)

Newborn feeding
- Ensure that the mother chooses feeding options before she leaves the facility or hospital after delivery.
- Support the mother’s choice of feeding option. (See Module 4, Infant Feeding in the Context of HIV Infection, for additional information).
- Provide training and observe proper feeding technique prior to discharge.

Signs and symptoms of postnatal infection
Review the following symptoms of infection before the new mother leaves the clinic or hospital and provide her with information on where to seek treatment for:
- Burning with urination
- Fever
- Foul smelling lochia
- Cough, sputum, shortness of breath
- Redness, pain, pus, or drainage from incision or episiotomy
- Severe lower abdominal tenderness

Education
- Instruct the mother on perineal and breast care
- Ensure that the mother knows how to dispose of potentially infectious materials such as lochia and blood-stained sanitary pads
**Family planning**

Contraception and child spacing should be discussed with every woman during antenatal care and again in the immediate postpartum period. The main family planning goals for the woman who is HIV-infected are:

- Preventing unintended pregnancy
- Appropriate child spacing, which can help reduce maternal and infant morbidity and mortality

(See Module 2, Overview of HIV Prevention in Mothers, Infants and Young Children for additional information.)

**Postpartum care of women with unknown HIV status**

Women whose HIV status is unknown should receive the same postpartum care as women with HIV infection (outlined above). They should be encouraged to be tested for HIV and to follow national recommendations for feeding their infants.

**HIV testing after delivery can assist women infected with HIV to:**

- Initiate post-exposure ARV prophylaxis for the infant
- Choose safer infant-feeding options

### Exercise 3.3 Immediate postpartum care of women who are HIV-infected: Case studies

<table>
<thead>
<tr>
<th>Purpose</th>
<th>To review postnatal management of the woman with HIV infection</th>
</tr>
</thead>
<tbody>
<tr>
<td>Duration</td>
<td>25 minutes</td>
</tr>
<tr>
<td><strong>Instructions</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Take a few minutes to become familiar with the national policies on postpartum care.</td>
</tr>
<tr>
<td></td>
<td>Review the case studies below on immediate postpartum care of women infected with HIV and women with unknown HIV status.</td>
</tr>
<tr>
<td></td>
<td>Think about the questions posed in the case studies and participate in the group discussion to answer the questions.</td>
</tr>
<tr>
<td></td>
<td>Review the key points written on the flipchart.</td>
</tr>
<tr>
<td></td>
<td>Share your perspective on the similarities and differences in these case studies and the situations you encounter in your clinical setting.</td>
</tr>
<tr>
<td></td>
<td>Describe experiences that you have found challenging in the postnatal care setting.</td>
</tr>
</tbody>
</table>
**Case study 1**

Deborah presented to the labour and delivery ward without having had an HIV test during her pregnancy. The result of the rapid HIV test performed during labour was positive. When told of the test result, Deborah became upset but agreed to take the NVP tablet. Subsequently, she had an uneventful labour and delivered a 2.4 kg healthy boy she named William. Although breastmilk substitute is available at the clinic, Deborah is determined to breastfeed her baby. It is now two hours after her delivery and she is resting. Her mother and husband are staying with her.

*What postpartum care does she require?*

*What HIV-specific services does she need?*

*What can you accomplish before she leaves the facility in 24 hours?*

**Case study 2**

Consuelo, who is HIV-positive, has been following the ZDV and NVP regimen for herself and her child. After a short labour, she delivered a 2 kg girl named Samantha. Consuelo has chosen to use breastmilk substitute; she will be discharged in 48 hours.

*What postpartum care does she require?*

*What HIV-specific services does she need?*

*What can you do to support her infant-feeding choice?*

*What services can you provide to her before she leaves in 24 hours?*

*What continuing support do you anticipate providing to her?*
SESSION 5 Immediate Newborn Care of Infants who are HIV-Exposed and Infants with Unknown HIV Status

The immediate care of the newborn exposed to HIV follows standard practice. Regardless of the mother’s HIV status, all infants are kept warm after birth and are handled with gloves until maternal blood and secretions have been washed off.

Immediate newborn care

- Maintain universal precautions throughout care and treatment. Wear gloves when giving injections, and clean all injection sites with surgical spirits. Dispose of all needles according to facility policy.
- Clamp cord immediately after birth, and avoid milking the cord. Cover the cord with gloved hand or gauze before cutting.
- Wipe infant’s mouth and nostrils with gauze when the head is delivered.
- Use suction only when meconium-stained liquid is present. Use either mechanical suction at less than 100 mm Hg pressure or bulb suction, rather than mouth-operated suction.
- Wipe the infant dry with a towel.
- Determine the mother’s feeding choice. If she is using breastmilk substitute, place the infant on her body for skin-to-skin contact and provide help with the first feeding. If she is breastfeeding, place the infant on the mother’s breast.
- Administer vitamin K, silver nitrate eye ointment, and Bacille Calmette Guérin (BCG) according to national guidelines.

ARV prophylaxis

ARV prophylaxis should be administered to the newborn according to country protocol. (See Appendix 3-A).

Follow-up newborn care

Care of the newborn baby should follow standard practices. Care for babies exposed to HIV should follow the approach described in Module 7, Linkages to Treatment, Care and Social Support for Mothers and Families with HIV Infection.

Infants born to mothers with unknown HIV status

In the immediate postpartum period, the goal is to reduce MTCT by minimising newborn exposure to maternal blood and body fluids and by providing ARV prophylaxis to the newborn. When HIV testing is unavailable or the mother’s HIV status is unknown, newborn care should follow national or local policy.

- Newborns of mothers with unknown HIV status should be tested as soon as possible after birth, if the mother consents.
- In some high-prevalence settings, national policy could recommend that all babies be given a single oral dose of nevirapine 2 mg/kg liquid suspension as soon as possible after birth, if the mother consents, whether or not the mother has been tested for HIV.
- The mother should receive counselling about feeding her infant, as described in Module 4, Infant Feeding in the Context of HIV Infection.
Exercise 3.4 Immediate newborn care of infants who are HIV-exposed: case studies

<table>
<thead>
<tr>
<th>Purpose</th>
<th>To review ARV prophylaxis for and newborn care of infants exposed to HIV</th>
</tr>
</thead>
<tbody>
<tr>
<td>Duration</td>
<td>25 minutes</td>
</tr>
<tr>
<td>Instructions</td>
<td>- Take a few minutes to become familiar with the national policies on newborn care of infants exposed to HIV.</td>
</tr>
<tr>
<td></td>
<td>- Read the 2 case studies below on immediate newborn care of infants exposed to HIV.</td>
</tr>
<tr>
<td></td>
<td>- Discuss your responses with other participants in the large group discussion.</td>
</tr>
</tbody>
</table>

**Case study 1**
Deborah has just delivered her son, William. She tested HIV-positive during labour.

*What HIV-specific infant interventions are required after the birth?*

*What are the components of follow-up care for William?*

*How can you help Deborah manage ongoing HIV-related care for herself and her infant?*

**Case study 2**
Samantha, the newborn daughter of Consuelo (who is HIV-positive), is irritable and cries often. Consuelo’s mother-in-law, who is visiting her at the facility and will be helping care for the infant after discharge, is worried. You overhear her repeatedly telling Consuelo that the baby needs breastmilk and that the breastmilk substitute is not satisfying the baby.

*What can you do to help Consuelo at this stressful time?*

*What support will Consuelo need from the PMTCT programme to continue using breastmilk substitute after discharge?*

**Home birth case study**
Louisa was diagnosed as HIV-positive during her one ANC visit prior to delivery at home. She has returned to the health centre 6 days after the birth of Teresa, her daughter. The baby appears to be happy, well hydrated, and thriving. Louisa remains convinced she is not infected with HIV and that the baby is not at risk. In fact, she did not give the NVP syrup to Teresa because the baby “didn’t need it” and Teresa is breastfeeding.

*Is this a typical response in your setting?*

*What services would you offer this mother?*

*What follow-up and referrals are necessary for this mother and her infant?*

*How will you deal with her denial of her diagnosis and risk for her infant?*
Module 3: Key Points

- Integrating PMTCT services into the essential package of ANC services promotes improved care for all pregnant women and provides the best opportunity for a successful PMTCT programme.
- Specific interventions to reduce MTCT include ARV treatment and prophylaxis, safer delivery procedures, and counselling and support for safe infant feeding.
- Using antiretroviral drugs for treatment and prophylaxis reduces the risk of MTCT. Longer-course combination regimens are more effective, but short-course prophylaxis regimens may be more feasible in some resource-constrained settings.
- PCP prophylaxis and the prevention and treatment of TB and malaria are part of comprehensive care for mothers infected with HIV and their infants.
- Safer delivery procedures include avoiding unnecessary invasive obstetrical procedures and offering the option of elective caesarean section when safe and feasible.
- Infant-feeding options to minimise the risk of MTCT require support and guidance throughout ANC, labour and delivery and postpartum.
APPENDIX 3-A Antiretroviral prophylaxis regimens to prevent MTCT

HIV-related treatment, care and support must be provided during the antenatal and postpartum periods. All HIV-exposed infants should be followed-up for diagnosis of HIV, prophylaxis of opportunistic infection and treatment, care and support.

All regimens are administered by mouth. Paediatric formulations are needed for all infant regimens. Efforts must be made to monitor for side effects and support maternal infant adherence.

<table>
<thead>
<tr>
<th>COURSE</th>
<th>ANTENATAL</th>
<th>INTRAPARTUM</th>
<th>POSTPARTUM</th>
<th>POSTNATAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zidovudine (ZDV) and nevirapine (NVP)</td>
<td>Mother: ZDV 300 mg twice a day starting at 28 weeks or as soon as possible thereafter</td>
<td>Mother: ZDV 300 mg at onset of labour and every 3 hours until delivery and single-dose NVP 200 mg at onset of labour OR ZDV 600 mg at onset of labour</td>
<td>None</td>
<td>Infant: NVP 2mg/kg oral suspension immediately after birth and ZDV 4 mg/kg twice a day for 7 days OR NVP 2 mg/kg oral suspension immediately after birth</td>
</tr>
<tr>
<td>ZDV</td>
<td>Mother: ZDV 300 mg twice a day starting at 28 weeks or as soon as possible thereafter</td>
<td>Mother: ZDV 600 mg at onset of labour OR ZDV 300 mg at onset of labour and every 3 hours until delivery</td>
<td>None</td>
<td>Infant: ZDV 4 mg/kg twice a day for 7 days OR ZDV 2 mg/kg 4 times a day for 7 days</td>
</tr>
<tr>
<td>ZDV and NVP for infant (when mother has received no ARV prophylaxis)</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Infant: NVP 2 mg/kg oral suspension immediately after birth and ZDV 4 mg/kg twice a day for 7 days. When ZDV oral suspension not available NVP 2 mg/kg as soon as possible after delivery and a dose of NVP 72 hours after birth</td>
</tr>
<tr>
<td>NVP</td>
<td>None</td>
<td>Mother: Single-dose NVP 200 mg at onset of labour</td>
<td>None</td>
<td>Infant: NVP 2 mg/kg oral suspension immediately after birth</td>
</tr>
<tr>
<td>ZDV and lamivudine (3TC)</td>
<td>Mother: ZDV 300 mg and 3TC 150 mg twice a day starting at 28 weeks or as soon as possible thereafter</td>
<td>Mother: ZDV 300 mg every 3 hours until delivery and 3TC 150 mg every 12 hours until delivery</td>
<td>None</td>
<td>Infant: ZDV 4 mg/kg and 3TC 2 mg/kg twice a day for 7 days</td>
</tr>
</tbody>
</table>

= First choice regimen
## APPENDIX 3-A Antiretroviral prophylaxis regimens to prevent MTCT (continued)

<table>
<thead>
<tr>
<th>COURSE</th>
<th>ANTENATAL</th>
<th>INTRAPARTUM</th>
<th>POSTPARTUM</th>
<th>POSTNATAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>ZDV and 3TC</td>
<td>None</td>
<td><strong>Mother:</strong>&lt;br&gt;ZDV 600 mg and 3TC 150 mg at onset of labour followed by ZDV 300 mg every 3 hours and 3TC 150 mg every 12 hours until delivery</td>
<td><strong>Mother:</strong>&lt;br&gt;ZDV 300 mg and 3TC 150 mg twice a day for 7 days</td>
<td><strong>Infant:</strong>&lt;br&gt;ZDV 4 mg/kg and 3TC 2 mg/kg twice a day for 7 days</td>
</tr>
<tr>
<td>ZDV + 3TC + saquinavir (SQV/r) * (Consider for MTCT prophylaxis in women not needing ARV therapy)</td>
<td><strong>Mother:</strong>&lt;br&gt;ZDV 300 mg, 3TC 150 mg and SQV/r 1000 mg/100 mg twice a day starting at 36 weeks or as soon as possible thereafter</td>
<td><strong>Mother:</strong>&lt;br&gt;Continue antenatal dosing schedule</td>
<td>None</td>
<td><strong>Infant:</strong>&lt;br&gt;NVP 2 mg/kg oral suspension immediately after birth&lt;br&gt;OR&lt;br&gt;ZDV 4 mg/kg twice a day for 7 days&lt;br&gt;OR&lt;br&gt;NVP 2 mg/kg oral suspension immediately after birth and ZDV 4 mg/kg twice a day for 7 days</td>
</tr>
<tr>
<td>ZDV or stavudine (d4T) + 3TC + NVP+ (This treatment regimen in pregnant women also provides MTCT prophylaxis.)</td>
<td><strong>Mother:</strong>&lt;br&gt;ZDV 300 mg and 3TC 150 mg and NVP 200 mg twice a day&lt;br&gt;OR&lt;br&gt;d4T 40 mg, 3TC 150 mg and NVP 200 mg twice a day starting at 36 weeks or as soon as possible thereafter</td>
<td><strong>Mother:</strong>&lt;br&gt;Continue antenatal dosing schedule</td>
<td>None</td>
<td><strong>Infant:</strong>&lt;br&gt;NVP 2 mg/kg oral suspension immediately after birth&lt;br&gt;OR&lt;br&gt;ZDV 4 mg/kg twice a day for 7 days&lt;br&gt;OR&lt;br&gt;NVP 2 mg/kg suspension immediately after birth and ZDV 4 mg/kg twice a day for 7 days</td>
</tr>
</tbody>
</table>

* In women who do not require ARV, alternative triple-combination regimens for MTCT prophylaxis may be considered. If the woman is in the third trimester of pregnancy, these regimens may include ZDV + 3TC + nelfinavir (NFV) or ZDV + 3TC + efavirenz (EFV).

+ In women who require ART, this is the recommended first-line regimen. However, in the third trimester of pregnancy, a regimen consisting of ZDV (or d4T) + 3TC + EFV may be considered.
**APPENDIX 3-B**  Clinical situations and recommendations for the use of antiretroviral drugs in pregnant women and women of childbearing potential in resource-constrained settings

<table>
<thead>
<tr>
<th>Clinical Situation</th>
<th>Recommendation</th>
</tr>
</thead>
</table>
| **A:** HIV-infected women with indications for initiating ARV treatment who may become pregnant | **First-line regimen:** ZDV + 3TC + NVP or d4T + 3TC + NVP  
Efavirenz (EFV) should be avoided in women of childbearing age, unless effective contraception can be assured. Exclude pregnancy before starting treatment with EFV. |
| **B:** HIV-infected women receiving ARV treatment who become pregnant | **Women**  
- Continue the current ARV regimen unless it contains EFV. If it does, substitution with NVP or a PI should be considered if in the 1st trimester.  
- Continue the same ARV regimen during the intrapartum period and after delivery.  
**Infants**  
- If born to women receiving either 1st or 2nd-line ARV regimens: 1-week ZDV OR single-dose NVP OR 1-week ZDV and single-dose NVP |
| **C:** HIV-infected pregnant women with indications for ARV treatment | **Women**  
- Follow the treatment guidelines as for non-pregnant adults except that EFV should not be given in the 1st trimester.  
- First line regimens: ZDV + 3TC + NVP or d4T + 3TC + NVP  
- Consider delaying therapy until after the 1st trimester, although in severely ill women the benefits of early therapy clearly outweigh the potential risks.  
**Infants**  
- 1-week ZDV OR single-dose NVP OR 1-week ZDV and single-dose NVP |
Clinical situations and recommendations for the use of antiretroviral drugs in pregnant women and women of childbearing potential in resource-constrained settings (continued)

<table>
<thead>
<tr>
<th>Clinical Situation</th>
<th>Recommendation</th>
</tr>
</thead>
</table>
| **D:** HIV-infected pregnant women without indications for ARV treatment<sup>1</sup> | **First-choice regimen:** ZDV and NVP  
Women  
- ZDV starting at 28 weeks or as soon as possible thereafter. Continue ZDV at the same dose in labour. In addition, women should receive single-dose NVP at the onset of labour.  
Infants  
- Single-dose NVP and 1-week ZDV<sup>3</sup>  
**Alternative regimen:** NVP only  
Women  
- Single-dose NVP  
Infants  
- Single-dose NVP  
**Alternative regimen:** ZDV only  
Women  
- ZDV starting at 28 weeks or as soon as possible thereafter. Continue in labour.  
Infants  
- 1-week ZDV<sup>3</sup>  
**Alternative regimen:** ZDV + 3TC  
Women  
- ZDV + 3TC starting at 36 weeks or as soon as possible thereafter. Continue in labour and for 1 week postpartum.  
Infants  
- 1-week ZDV + 3TC |  
| **E:** HIV-infected pregnant women with indications for starting ARV treatment<sup>1</sup> but treatment is not yet available | Follow the recommendations in Situation D, but preferably use the most efficacious regimen that is available and feasible. |  
| **F:** HIV-infected pregnant women with active tuberculosis | If ARV treatment is initiated, consider<sup>4</sup>: (ZDV or d4T) + 3TC + SQV/r. If treatment is initiated in the third trimester (ZDV or d4T) + 3TC + EFV can be considered. If ARV treatment is not initiated, follow the recommendations in Situation D. |
## APPENDIX 3-B

Clinical situations and recommendations for the use of antiretroviral drugs in pregnant women and women of child-bearing potential in resource-constrained settings (continued)

<table>
<thead>
<tr>
<th>Clinical Situation</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>G:</strong> Pregnant women of unknown HIV status at the time of labour or women in labour known to be HIV-infected who have not received ARV drugs before labour</td>
<td>If there is time, offer HIV testing and counselling to women of unknown status and if positive, initiate intrapartum ARV prophylaxis.</td>
</tr>
<tr>
<td><strong>Women</strong></td>
<td>Single-dose NVP. If in advanced labour do not give the dose but follow the recommendations in Situation H.</td>
</tr>
<tr>
<td><strong>Infants</strong></td>
<td>Single-dose NVP</td>
</tr>
<tr>
<td><strong>Women</strong></td>
<td>ZDV + 3TC in labour and 1-week ZDV + 3TC postpartum</td>
</tr>
<tr>
<td><strong>Infants</strong></td>
<td>1-week ZDV+3TC</td>
</tr>
<tr>
<td>If there is insufficient time for HIV testing and counselling during labour, then offer testing and counselling as soon as possible postpartum. Follow the recommendations in Situation H for women testing positive postpartum.</td>
<td></td>
</tr>
<tr>
<td><strong>H:</strong> Infants born to HIV-infected women who have not received any ARV drugs</td>
<td><strong>Infants</strong></td>
</tr>
<tr>
<td><strong>Infants</strong></td>
<td>Single-dose NVP as soon as possible after birth and 1-week ZDV</td>
</tr>
<tr>
<td>If the regimen is started more than 2 days after birth, it is unlikely to be effective.</td>
<td></td>
</tr>
</tbody>
</table>

1 WHO recommendations for initiating ARV treatment in HIV-infected adolescents and adults. If CD4 testing is available it is recommended to offer ARV treatment to patients with: WHO Stage IV disease irrespective of CD4 cell count, WHO Stage III disease with consideration of using CD4 cell counts less than 350 $10^6$ cells/L to assist decision-making and WHO Stage I and II disease in the presence of a CD4 cell count less than 200 $10^6$ cells/L. If CD4 testing is unavailable, it is recommended to offer ARV treatment to patients with WHO Stage III and IV disease irrespective of total lymphocyte count or WHO Stage II disease with a total lymphocyte count less than 1200 $10^6$ cells/L.

2 Conduct clinical and laboratory monitoring as outlined in the 2003 revised WHO treatment guidelines.

3 Continuing the infant on ZDV for four to six weeks can be considered if the woman received antepartum ARV drugs for less than four weeks.

4 ABC can be used in place of SQV/r; however, experience with ABC during pregnancy is limited. In the rifampicin-free continuation phase of tuberculosis treatment, an NVP-containing ARV regimen can be initiated.
